mTOR has significant cross-talk with the Ras pathway, which is hyperactive in renal cancer cells, possibly through the induction of receptor tyrosine kinases (like, c-Met, EGFR (Epidermal Growth Factor Receptor) etc.). The gene discussed is MET; the disease is renal carcinoma.